Enlivex Therapeutics (Nasdaq:ENLV) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ENLV 주식 개요

는 자회사와 함께 이스라엘에서 임상 단계의 대식세포 재프로그래밍 면역 치료 회사로 운영되고 있습니다.

ENLV 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

위험 분석

수익은 향후 3년간 연평균 17.6% 씩 감소할 것으로 예상됩니다.

수익이 1백만 달러 미만인 경우 ( $0 )

의미 있는 시가총액이 없습니다. ( $27M )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

+ 1 더 많은 위험

Enlivex Therapeutics Ltd. 경쟁사

QSAM Biosciences

OTCPK:QSAM

US$34.5m

Tempest Therapeutics

NasdaqCM:TPST

US$34.5m

Quince Therapeutics

NasdaqGS:QNCX

US$34.6m

Sio Gene Therapies

OTCPK:SIOX

US$34.8m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Enlivex Therapeutics
과거 주가
현재 주가	US$1.64
52주 최고치	US$4.59
52주 최저치	US$1.15
베타	1.03
11개월 변경	26.15%
3개월 변경 사항	18.84%
1년 변경 사항	3.80%
33년 변화	-82.72%
5년 변화	-84.15%
IPO 이후 변화	-84.07%

최근 뉴스 및 업데이트

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Sep 13

Recent updates

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Sep 13

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Apr 04

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Dec 13

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Jul 25

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Apr 05

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Nov 16

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Sep 30

Enlivex to gets US patent covering use of cell therapy Allocetra

Sep 06

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Aug 29

Envilex Therapeutics reports Q2 results

Aug 22

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Jul 08

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Jul 06

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Mar 23

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Nov 25

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Aug 12

Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy

Jun 15

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Jan 11

Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?

Nov 19

주주 수익률

	ENLV	US Biotechs	US 마켓
7D	8.6%	-2.9%	0.9%
1Y	3.8%	18.9%	32.3%

수익률 대 산업: ENLV 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ENLV 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ENLV's price volatile compared to industry and market?
ENLV volatility
ENLV Average Weekly Movement	9.0%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: ENLV 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ENLV 의 주간 변동성은 지난 1년 동안 16% 에서 9% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	n/a	Oren Hershkovitz	www.enlivex.com

엔리벡스 테라퓨틱스는 자회사와 함께 이스라엘에서 임상 단계의 대식세포 재프로그래밍 면역 치료 회사로 운영되고 있습니다. 이 회사의 제품 파이프라인은 패혈증으로 인한 장기 기능 장애 치료를 위한 임상 2상 시험 중인 알로세트라(Allocetra)입니다. 또한 중등도 무릎 골관절염 및 말기 무릎 골관절염 치료를 위한 알로세트라를 개발 중이며 임상 1상/2상을 진행 중입니다.

Enlivex Therapeutics Ltd. 기본 사항 요약

Enlivex Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ENLV 기본 통계
시가총액	US$34.25m
수익(TTM)	-US$22.29m
수익(TTM)	n/a

0.0x

P/S 비율

-1.5x

P/E 비율

ENLV 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ENLV 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$22.29m
수익	-US$22.29m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.07
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

ENLV 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ENLV 주식 개요

보상

위험 분석

Enlivex Therapeutics Ltd. 경쟁사

OTCPK:QSAM

US$34.5m

NasdaqCM:TPST

US$34.5m

NasdaqGS:QNCX

US$34.6m

OTCPK:SIOX

US$34.8m

가격 내역 및 성능

최근 뉴스 및 업데이트

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Recent updates

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

High number of new and inexperienced directors

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

New minor risk - Shareholder dilution

Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ in Patients with Sepsis

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Price target decreased by 20% to US$12.00

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd. (NasdaqCM:ENLV) announces an Equity Buyback for $1.5 million worth of its shares.

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd. Intends to Reduce its Workforce by Approximately 50%

Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States

Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

New major risk - Financial position

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (Crs) Resulting from Car T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Authorizations from French and Belgian Regulatory Agencies to Expand Its Phase II Sepsis Clinical Trial into France and Belgium

Enlivex Receives Allocetra Ind Clearance from the U.S. Food and Drug Administration for Treatment of Patients with Advanced Solid Malignancies

Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$15.00

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

Enlivex to gets US patent covering use of cell therapy Allocetra

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Enlivex Therapeutics Ltd. Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Envilex Therapeutics reports Q2 results

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Sheba Medical Center and Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Enlivex Therapeutics Ltd. Receives Israeli Ministry of Health Authorization for the Initiation of Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients

Enlivex Therapeutics Ltd. Announces Appointment of Roger J. Pomerantz to its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Appoints Roger J. Pomerantz to Its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Price target increased to US$33.00

Insufficient new directors

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand Its Phase IIb Trial Evaluating Allocetra in Severe and Critical Covid-19 Patients into Greece

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece